Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy

Overview of attention for article published in Nature Communications, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

news: 2 news outlets
twitter: 7 X users

patent: 4 patents
facebook: 1 Facebook page

Readers on

mendeley: 38 Mendeley

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 310,765 followers.

So proud to support the publish of another Nature paper! Our shRNA was used. 💪💪 Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy https://t.co/ZGJBPBER2z

Oncolytic virotherapy induced CSDE1 neoantigen, which restricts VSV replication and thereby enables disease progression, but can be targeted by vaccination against the CSDE1-P5S variant: https://t.co/ZKeciovCaj

.@MiteshBorad @LewisRobertsMD @RVilePhD #CancerImmunotherapy #OncolyticVirotherapy

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy https://t.co/Yqkv5LHZxP https://t.co/I5RKwp4Ngm

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.